Chae Ok Yun

USPTO Granted Patents = 18 (Patent Applications = 12)

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 9 (Patent Applications = 17)

Average Co-Inventor Count = 2.3

ph-index = 1

Forward Citations = 9(Granted Patents)

Company Filing History:

10 out of 12

Genemedicine Co., Ltd.

patents

6 out of 1,114

Industry-University Cooperation Foundation Hanyang University

patents

2 out of 321

Korea Research Institute of Bioscience and Biotechnology

where one patent can have more than one assignee

Years Active: 2014-2024

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11970715 - PH-sensitive and bioreducible polymer-virus complex for cancer treatment (2024-04-30),

2. 11850215 - Recombinant adenoviruses and stem cells comprising same (2023-12-26),

3. 11364272 - Anticancer composition comprising tumor-specific oncolytic adenovirus and immune checkpoint inhibitor (2022-06-21),

4. 11235072 - Adenovirus complex for gene delivery and gene iherapy (2022-02-01),

5. 11174465 - Ph-sensitive and bioreducible polymer-virus complex for cancer treatment (2021-11-16),

6. 11000590 - Virus-PCION complex having enhanced antitumor effect by using electromagnetic field (2021-05-11),

7. 10864283 - Composition for preventing or treating keloid or hypertrophic scars (2020-12-15),

8. 10849987 - Complex of adenovirus and PAMAM-PEG-Erbitux, and use thereof (2020-12-01),

9. 10722587 - Composition for intracellular delivery containing adenovirus protein VI-derived peptide and anticancer pharmaceutical composition containing same (2020-07-28),

10. 10611797 - Peptide having anticancer activity, and pharmaceutical composition and dietary supplement composition for preventing and treating cancer, both of which contain same as active ingredient (2020-04-07),

11. 10357564 - Virus-PCION complex having enhanced antitumor effect by using electromagnetic field (2019-07-23),

12. 10071126 - Conditionally replicating adenovirus to express REIC gene (2018-09-11),

13. 9974818 - PPSA and Pspa polymer-virus complex and pharmaceutical compositions comprising the same (2018-05-22),

14. 9920099 - Anti-cancer compositions containing Wnt decoy receptor (2018-03-20),

15. 9689000 - Gene delivery system having enhanced tumor-specific expression, and recombinant gene expression regulating sequence (2017-06-27),

Title: **Innovations by Chae Ok Yun: Pioneering Cancer Treatment Technologies**

Introduction

Chae Ok Yun is a notable inventor based in Seoul, South Korea, best known for his significant contributions to cancer treatment technology. With a remarkable portfolio of 18 patents, Yun has dedicated his research to developing innovative solutions that enhance the effectiveness of medical treatments, particularly concerning cancer.

Latest Patents

Among his latest inventions, Yun has developed a pH-sensitive and bioreducible polymer-virus complex for cancer treatment. This novel complex has been designed to destroy tumor cells more effectively by increasing the efficiency of virus transduction. The polymer comprises an escapable portion from immune reactions, a chargeable portion containing amine groups, and a bioreducible portion with disulfide linkages. This invention not only provides a pharmaceutical composition containing the polymer-virus complex but also outlines methods for treating cancer using this advanced composition.

Another significant invention by Yun includes recombinant adenoviruses capable of being efficiently introduced into stem cells. These adenoviruses exhibit excellent survivability in vivo and effectively treat tumor cells. The gene delivery composition and the pharmaceutical application of these stem cells position this invention as a promising anticancer drug, especially when administered systemically and at lower doses.

Career Highlights

Chae Ok Yun has made substantial strides in the field of medical research, focusing on leveraging molecular biology techniques to innovate cancer therapies. His research has shown a profound impact in pharmaceutical formulations, particularly in enhancing therapeutic outcomes with reduced toxicity.

Collaborations

Throughout his career, Yun has collaborated with esteemed organizations, including Genemedicine Co., Ltd. and the Industry-University Cooperation Foundation at Hanyang University. He has also worked alongside notable coworkers such as A-Rum Yoon and Misun Won, who have contributed to advancing his research endeavors.

Conclusion

Chae Ok Yun continues to be a leading force in the realm of cancer treatment innovation. His groundbreaking patents and collaborations reflect his commitment to improving therapeutic strategies and patient outcomes in cancer care. As he progresses in his research, the medical community eagerly anticipates the future developments and contributions he will continue to bring to the field.

This text is generated by artificial intelligence and may not be accurate.